LBSP Favicon
VarmX Secures IND Approval for Phase 3 Trial of VMX-C001 in Emergency Surgery

VarmX Secures IND Approval for Phase 3 Trial of VMX-C001 in Emergency Surgery

VarmX has received IND approval for its Phase 3 trial of VMX‑C001, a recombinant factor X variant designed to neutralize FXa‑inhibiting anticoagulants during emergency surgery. Backed by robust Phase 1 data and boosted by a €15 million EIC investment, this step positions VMX‑C001 to meet a gap in urgent haemostasis care.

Key Region Leiden launch

Key Region Leiden launch

𝗛𝗼𝘄 𝗱𝗼 𝘄𝗲 𝘁𝘂𝗿𝗻 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗸𝗻𝗼𝘄𝗹𝗲𝗱𝗴𝗲 𝗶𝗻𝘁𝗼 𝗿𝗲𝗮𝗹 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀, 𝗳𝗮𝘀𝘁𝗲𝗿, 𝘀𝗺𝗮𝗿𝘁𝗲𝗿, 𝗮𝗻𝗱 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿? That’s the question Key Region Leiden is working to answer....

Algemene Rekenkamer (Court of Audit) visits LBSP

Algemene Rekenkamer (Court of Audit) visits LBSP

The Court of Audit visited LBSP to explore how science and entrepreneurship create public value, with stops at TNO, Peregrion, NTrans, and VarmX sparking discussion on biotech innovation.

Life Sciences Café June Edition

Life Sciences Café June Edition

Thank you to everyone who joined us last Thursday at Grand Café de Stal. The room was full of energy, curiosity, and conversation as we explored the...